Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
11 Outubro 2023 - 8:14PM
Business Wire
Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the
“Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced the pricing of an
underwritten offering of (i) 8,253,895 shares of its common stock
and accompanying common stock warrants to purchase an aggregate of
6,190,418 shares of common stock, and (ii) to certain investors in
lieu of common stock who so choose, pre-funded warrants to purchase
up to an aggregate of 1,571,093 shares of common stock and
accompanying common stock warrants to purchase up to an aggregate
of 1,178,320 shares of common stock. Each share of common stock and
accompanying common stock warrant are being sold together at a
combined public offering price of $6.514, and each pre-funded
warrant and accompanying common stock warrant are being sold
together at a combined public offering price of $6.513. The
aggregate gross proceeds of the offering are expected to be
approximately $64 million, before deducting underwriting discounts
and commissions and other estimated offering expenses. Each
pre-funded warrant will have an exercise price of $0.001 per share,
will be exercisable immediately and will be exercisable until all
of the pre-funded warrants are exercised in full. Each common stock
warrant will have an exercise price of $8.025 per share, will be
exercisable immediately and will expire 5 years from the date of
issuance.
All of the securities are being offered by Astria. The offering
is expected to close on or about October 16, 2023, subject to
satisfaction of customary closing conditions.
Jefferies and Evercore ISI are acting as joint book-running
managers for the offering. LifeSci Capital and Oppenheimer &
Co. are acting as co-lead managers.
The securities described above are being offered pursuant to a
shelf registration statement on Form S-3 (File No. 333-271848),
which was declared effective by the Securities and Exchange
Commission (the “SEC”) on May 23, 2023. The offering is being made
only by means of a prospectus supplement and the accompanying
prospectus. A final prospectus supplement relating to the offering
will be filed with the SEC and will be available at www.sec.gov.
When available, copies of the final prospectus supplement and the
accompanying prospectus may be obtained for free by contacting
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, by telephone at (877)
821-7388, or by email at Prospectus_Department@Jefferies.com; or
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, NY 10055, or by telephone at
(888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. STAR-0310 is a monoclonal antibody OX40 antagonist in
preclinical development for the treatment of atopic dermatitis.
Cautionary Note Regarding Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
anticipated completion of the offering and the expected gross
proceeds of the offering, among other things, statements containing
the words “believes,” “anticipates,” “plans,” “expects,” “may” and
similar expressions, constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including: risks and uncertainties associated with market
conditions, the satisfaction of customary closing conditions
relating to the offering, as well as uncertainties inherent in the
initiation and completion of preclinical studies and clinical
trials and clinical development of the Company’s product
candidates; whether interim results from a clinical trial will be
predictive of the final results of the trial or the results of
future trials; expectations for regulatory approvals to conduct
trials or to market products; availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements; other matters that could
affect the availability or commercial potential of the Company’s
product candidates; and general economic and market conditions and
other factors discussed in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2022, which is on file with the SEC, and in other
filings that the Company may make with the SEC in the future. In
addition, the forward-looking statements included in this press
release represent the Company’s views as of the date of this press
release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231011085613/en/
Investor Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024